Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124608 | 0.90 | EGFR (0.44) | EGFRERBB2ERBB4CSF1RKDM4E | |
| SCHEMBL7125158 | 0.86 | EGFR (0.42) | EGFRERBB2ERBB4KDRBRAF | |
| SCHEMBL7123201 | 0.86 | EGFR (0.56) | EGFRERBB2ERBB4KLK7 | |
| SCHEMBL7118153 | 0.83 | EGFR (0.56) | EGFRERBB2ERBB4KLK7 | |
| SCHEMBL7130779 | 0.82 | EGFR (0.39) | EGFRERBB2ERBB4EPHX2KDR | |
| SCHEMBL7127864 | 0.81 | EGFR (0.38) | EGFREPHX2KDRBRAFCSF1R | |
| SCHEMBL7126747 | 0.80 | EGFR (0.39) | EGFRERBB2ERBB4CSF1RFLT3 | |
| SCHEMBL7128565 | 0.77 | EGFR (0.45) | EGFRERBB2ERBB4KDRCSF1R | |
| SCHEMBL7120343 | 0.76 | EGFR (0.61) | EGFRERBB2ERBB4 | |
| SCHEMBL7127860 | 0.76 | EGFR (0.38) | EGFRERBB2ERBB4KDRKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.